Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
4
×
life sciences
national blog main
national top stories
new york blog main
4
×
new york top stories
clinical trials
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
amgen
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
eli lilly
indiana blog main
indiana top stories
national
new york
pfizer
raleigh-durham blog main
raleigh-durham top stories
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abiraterone
ac immune
acorda therapeutics
aduro biotech
agenus
akcea therapeutics
What
drug
4
×
year
4
×
big
companies
fda
medicines
therapies
aces
ago
akcea
alnylam
alzheimer’s
amyloidosis
announced
approval
approved
arguments
attr
available
battle
bio
ceo
cholesterol
class
commercialized
competitors
debilitating
decades
different
disease
drugs
fail
flexible
gene
genetic
inclisiran
increases
key
latest
lowering
Language
unset
Current search:
drug
×
year
×
" new york blog main "
×
" boston top stories "
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More